Results 81 to 90 of about 172,168 (267)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms

open access: yesJournal of Hematology & Oncology, 2016
Background Acquired imatinib (IM) resistance is frequently characterized by Bcr-Abl mutations that affect IM binding and kinase inhibition in patients with chronic myelogenous leukemia (CML).
Xiaoying Lan   +13 more
doaj   +1 more source

Patient‐specific genomic measurable residual disease markers for monitoring acute myeloid leukaemia and myeloid malignancy

open access: yesBritish Journal of Haematology, EarlyView.
Standardised DNA based measurable residual disease (MRD) monitoring is possible for acute myeloid leukaemia (AML) and myeloid malignancy patients. Targeted next‐generation sequencing (NGS) and RNA‐seq permit marker development for clinically identified lesions and whole genome sequencing (WGS) permits MRD marker development in patients without ...
Libby Huang   +45 more
wiley   +1 more source

Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. [PDF]

open access: yesPLoS ONE, 2013
BCR-ABL kinase domain inhibition can be used to treat chronic myeloid leukemia. The inhibitors such as imatinib, dasatinib and nilotinib are effective drugs but are resistant to some BCR-ABL mutations.
Karunakar Tanneeru, Lalitha Guruprasad
doaj   +1 more source

Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex

open access: yesOncotarget, 2017
Treatment of BCR-ABL+ human leukemia has been significantly improved by ABL tyrosine kinase inhibitors (TKIs), but they are not curative for most patients and relapses are frequently associated with BCR-ABL mutations, warranting new targets for improved treatments.
Chen, Min   +5 more
openaire   +3 more sources

New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs

open access: yesPharmaceutics
Bcr-Abl is an oncoprotein with aberrant tyrosine kinase activity involved in the progression of chronic myeloid leukemia (CML) and has been targeted by inhibitors such as imatinib and nilotinib.
Thalia Delgado   +12 more
doaj   +1 more source

MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia

open access: yesScientific Reports, 2015
Accumulating evidences demonstrated that the induction of epithelial-mesenchymal transition (EMT) and aberrant expression of microRNAs (miRNAs) are associated with tumorigenesis, tumor progression, metastasis and relapse in cancers, including chronic ...
Xi-Shan Zhu   +3 more
semanticscholar   +1 more source

Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold

open access: yesScientific Reports, 2015
The constitutively active tyrosine kinase BCR-ABL is the underlying cause of chronic myeloid leukemia (CML). Current CML treatments rely on the long-term use of tyrosine kinase inhibitors (TKIs), which target the ATP binding site of BCR-ABL.
Yen-Hua Huang   +6 more
semanticscholar   +1 more source

Opposing roles of acid phosphatase 1 (ACP1) and ACP3 in prostate cancer progression

open access: yesBJU International, EarlyView.
Objectives To evaluate the roles of intracellular acid phosphatase 1 (ACP1) and ACP3 expression as biomarkers of prostate cancer progression through a systematic review and meta‐analysis assessing associations with disease presence, tumour aggressiveness, and patient prognosis.
Alessandra V. de S. Faria   +3 more
wiley   +1 more source

Evaluation of Morpholino Antisense Oligos’ Role on BCR-ABL Gene Silencing in the K562 Cell Line [PDF]

open access: yesCell Journal, 2010
Objective: Chronic myeloid leukemia (CML) develops when a hematopoietic stem cellacquires the BCR/ABL fusion gene. This causes these transformed hematopoietic cellsto have a greater than normal proliferation rate.
Bahman Delalat   +6 more
doaj  

Post‐Hoc Long‐Read Sequencing Links Leukemic Mutation Status to Single‐Cell Transcriptomes

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Single‐cell RNA‐sequencing‐based characterization of cells that belong to the neoplastic clone is a major challenge in hematologic neoplasms, where malignant and normal cells coexist. Confident molecular profiling requires simultaneous analysis of gene expression and genetic mutations in individual cells, an ability that is not supported by ...
Sofia Papavasileiou   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy